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Complex regional pain syndrome type I (CRPS I) is a disabling syndrome 1 associated with continuous pain that is not related to the territory of a single nerve and is disproportionate to the inciting event. 2 As there is no objective test available, diagnosis of CRPS I is based solely on signs and symptoms. 3 4 In line with these diagnostic dif®culties, therapy for CRPS I has also been unsatisfactory. Although many treatments are used, we recently found in a meta-analysis that most of them lack a sound scienti®c basis. 5 6 Spinal cord stimulation (SCS) is widely used in the treatment of CRPS I, 7±13 and we were able to show its effectiveness in a randomized controlled study.
14 Follow-up in this study, however, was only 6 months. As there is anecdotal evidence that the clinical effects of SCS decrease over time and there is controversy regarding the use of SCS in the cervical region, we undertook a prospective study to address these issues. We prospectively measured pain, global perceived effect, quality of life, complications and side-effects of SCS in 36 CRPS I patients. Of these, 19 had devices positioned in the cervical region and 17 in the lumbar region.
Patients and methods

Patients
The Hospital's Institutional Review Board approved the study protocol. The study started in 1997. Informed consent was obtained from all patients, who had to ful®l the diagnostic criteria for CRPS I as stated by the International Association for Study of Pain (IASP). 15 At the time of the study these criteria were the most valid diagnostic criteria available. In addition, patients had to show impaired function and extension of symptoms outside the area of trauma (Table 1) . Furthermore, disease duration was at least 6 months and conventional treatments (i.e. sympathetic block, transcutaneous electrical nerve stimulation and conventional pain medication) had failed.
Test stimulation
All patients initially underwent test stimulation. The patient was placed in the prone position after an i.v. injection of cefuroxim (1500 mg) had been given. A 5-cm vertical midline incision was performed over the thoracic or lumbar spine, depending on the affected extremity. The epidural space was localized with a Tuohy needle. For lumbar electrode placement, level L3±L4 was chosen. The cervical electrode was inserted between Th3 and Th4. Using direct uoroscopy, an SCS electrode (Pisces Quad lead, model 3487A; Medtronic, Minneapolis, MN, USA) was introduced via the needle into the epidural space and connected to an external pulse generator (model 3625; Medtronic). The optimal position was considered to have been reached when the paraesthesiae induced by stimulation totally covered the painful area. The needle was then withdrawn and the electrode was ®xed with special clips and connected to the external stimulator.
After a test period of 7 days the temporary lead was removed. During the test period, patients were advised to perform all normal daily activities in order to obtain a good impression of the implant's effect. The permanent SCS system was implanted when, during the testing period, the patient reported either at least 50% reduction in pain intensity as measured on a 10 cm visual analogue scale (VAS), which was anchored by the two extremes of pain (`no pain' on the left and`the worst possible pain' on the right), or`much improvement' on the seven-point global perceived effect (GPE) scale. The GPE was translated from English into Dutch.
14 The GPE categories include: best ever, much improved, improved, not improved/not worse, much worse, and worst ever.
Implantation of the SCS system
The Quad lead was implanted in the same fashion as the test lead. After the lead had been positioned, the patient was sedated and a pulse generator (Itrel 3, model 7425; Medtronic) was implanted in the subcutaneous tissue in the left lower anterior abdominal wall, and connected to the electrode by a tunnelled extension lead (model 7495±51 or 7495±66; Medtronic). After closing the skin, the pulse generator was activated and adjusted using a console programmer (model 7432; Medtronic). Initial stimulation was started at a rate of 85 Hz and a pulse width of 210 ms. Patients could control the stimulation intensity by adjusting the amplitude from 0 to 10 V with a patient programmer (model 7434-NL; Medtronic). After implantation, patients remained in the hospital for 24 h, during which period they received two doses of cefuroxim (750 mg) i.v. The following day, after the position of the electrode had been veri®ed by x-ray, the patient was discharged. Further adjustments in the programming could be made on an outpatient basis. After implantation no restrictions were placed on patient activities.
Patient assessment during follow-up
The assessments were done before treatment and 6, 12 and 24 months after implantation. All patients were asked to score their pain three times per day over the course of 4 days on a 10-cm VAS. 16±18 In addition, all patients rated the GPE on pain on a seven-point scale, as indicated above. All patients completed the Euroqol 5D (EQ-5D) 19 before the treatment and at follow-up after 1 and 2 yr. The EQ-5D consists of two parts. The ®rst part records self-reported health problems in ®ve dimensions: mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension is subdivided into three categories: no problem, moderate problems and extreme problems. By combining one category from each of the ®ve dimensions, a total of 243`health states' are de®ned. The second part records the perception of the patients' overall health on a 100-mm VAS (0 denoting death and 100 perfect health). The data of the EQ-5D are represented in three distinct forms: 20 (i) as a pro®le, based on the patient's category of problem in each of the ®ve dimensions (EQ-5D pro®le); (ii) as a social score by applying a suitable weighting system obtained from the UK national survey; some patients score negatively, indicating that, from a social perspective their state is regarded as worse than death; and (iii) on a VAS, representing a quantitative measure of the patient's valuation of his own global health status (EQ-5D VAS).
The questionnaires were sent to the patients by post. They were asked to complete the questionnaires and return them by post.
Complications and adverse effects were also documented during clinic follow-up. Complications were de®ned as unpleasant, new, physical experiences for the patient, and included spinal tap, post-spinal headache, and infection. Adverse effects were de®ned as technical failure, including: technical procedure problems during the implantation; revision of the pulse generator pocket; lead dislocation; defective pulse lead; pulse generator failure; device removal; device re-implantation; and pain resulting from pulse generator, lead or plug and electrical stimulation elsewhere.
Statistical analysis
Changes in variables were tested using the paired t-test and the McNemar test. Differences between cervical and lumbar SCS were tested using two-way ANOVA and the c 2 test.
The change/progress of pain, using more than two points of time, was analysed with repeated measures ANOVA with the VAS 0.5, 1 and 2 yr after the intervention. P<0.05 was considered statistically signi®cant.
Results
Patients
The study population consisted of 36 consecutive patients, who were classi®ed according to the location of the SCS implantation, i.e. cervical or lumbar. As demonstrated in Table 2 , there were 19 patients with a cervical device and 17 patients with a lumbar device. In the cervical group there were eight male and 11 female patients, with a mean age of 38 yr and a mean VAS of 7 cm. Four male and 13 female patients received a lumbar SCS. The mean age of these patients was 42 yr and the mean VAS was 7.6 cm. All patients were treated with the SCS for at least 2 yr. In four patients the SCS was removed after 1 yr and one patient in the cervical group refused further participation without explanation 1 yr after implantation. Forouzanfar et al.
VAS and EQ-5D
The results of the VAS and EQ-5D are shown in Table 3 . At all follow-up periods the pain intensity was decreased compared with the baseline (P<0.001); the VAS scores for individual patients are shown in Table 4 . The pain intensity increased with time, as demonstrated in Figure 1 . The repeated measures ANOVA showed a statistically signi®-cant, linear increase in the VAS (P=0.03). We found no signi®cant differences in outcome between cervical and lumbar SCS. At all follow-up measurements, at least 50% of the patients with cervical SCS and 40% of the patients with lumbar SCS reported a relative pain reduction of at least 50%, as measured on the VAS. According to the GPE, at least 42% of the cervical SCS and 47% of the lumbar SCS reported at least`much improvement' during measurements.
Health-related quality of life (HRQL)
As demonstrated in Table 3 , HRQL of all patients before treatment was lower than any follow-up score (P<0.05). The personal HRQL score also demonstrated an increase for each follow-up period (P<0.02). We found this in all patients. In Figure 2 the unweighted response to the EQ-5D is presented at baseline and at two follow-up periods. At the follow-up periods the number of patients reporting`extreme problems' for the categories`usual activities' and`pain and discomfort' decreased in both the cervical and the lumbar group (P<0.01). In the dimension anxiety and depression, 50% of the patients noted`no problems' at baseline, which increased in both groups at the follow-up periods (P<0.02). The other EQ-5D dimensions did not change signi®cantly. Differences between cervical and lumbar SCS were not signi®cant. Complications Table 5 shows the complications and adverse effects during and after implantation of the SCS device. A total of 23 patients (10 patients with a lumbar device and 13 patients with a cervical device) developed complications or adverse effects. We encountered complications related to implantation of the temporary system as well as the permanent system in six patients. Three of these patients also had adverse effects, which will be discussed later. In three patients a spinal tap with a lumbar SCS complicated implantation of the temporary lead. One patient suffered a post-spinal headache, and a blood patch was required. In one patient with CRPS I of the upper extremity it was not possible to localize the epidural space at the usual level. Therefore, the implantation of the extended lead had to be performed at a lower thoracic level.
Thirty-one adverse effects were noted in 20 patients. Because of a rotation of the pulse generator and subsequent painful sensations, revision of the pulse generator pocket was performed in ®ve patients. Substantial weight loss resulted in pocket revision in two other cases. Inadequate paraesthesiae or paraesthesiae in other locations required repositioning of the lead in one patient with CRPS I in the lower extremity and in ®ve patients with affected upper extremity. In two cases no satisfactory repositioning was obtained. Lead failure resulted in replacement in four patients. Because of technical failure, replacement of the pulse generator was needed in two cases.
The complete SCS system was removed in two patients with a cervical SCS and two patients with a lumbar SCS, which resulted in stopping the treatment. Dislocation of the cervical lead occurred more frequently, but this was not signi®cant compared with the lumbar group (P=0.17). In one patient the complete permanent system was removed because of suspicion of infection. However, bacteriological cultures were negative. Reimplantation resulted in the same complaints as the ®rst implant, which may indicate a reaction to the constituents of the implant. The reimplant was also removed. One patient suffered from secondary ulcerative colitis (UC). A relationship between the SCS system and UC disease activity was suggested, which resulted in the removal of the lead system. 13 In one case the system was removed because of increased pain during stimulation, and in one other because of inability to obtain effective stimulation.
Discussion
CRPS is a pain syndrome of unclear pathophysiology and typically affects the hand and arm or foot and leg. The diagnosis of CRPS is a clinical diagnosis and is based on absolute and relative criteria developed by IASP in 1994. Pain and impaired function are mandatory for the diagnosis. Therefore, the goal of treatment in patients with CRPS is to relieve pain and improve function. Recent reviews have shown 5 21 22 that the number of effective therapies in the treatment of CRPS is limited.
Spinal cord stimulation has been suggested as a therapy for pain relief when other treatment modalities have failed. 23 The exact physiological mechanism of pain relief by SCS in patients with CRPS is poorly understood. It has been suggested that SCS works through a spectrum of neurophysiological mechanisms. 24 Studies in nerve-lesioned rats showed that SCS results in increased release of GABA in the dorsal horn, resulting in a decrease in the excitatory amino acids glutamate and aspartate. 25 The clinical effects of SCS in CRPS have been established in a limited number of uncontrolled studies. 12 26 We recently documented the clinical shortterm effects in a randomized controlled study. 14 Little is known about the long-term effect and complications of SCS.
In 44±61% of patients the CRPS is located in the upper extremity. 27 28 This means that in most patients treatment with SCS cervical lead placement is indicated. It is widely held that SCS should be used with caution in the cervical region. In the cervical region, the posterior epidural space is the smallest and may prevent adequate lead placement. The mobility of the cervical spine and the local anatomy should restrict effectiveness and may lead to more and worse complications. The present study addresses these two issues.
Contrary to the prevailing view, we found that the SCS device was slightly more effective in patients with a cervical implant than a lumbar implant, although this difference was not signi®cant. All patients reported a signi®cant reduction in pain relief, of at least 50% after 6 months after implantation.
After 1 and 2 yr of follow-up there was a slight but signi®cant increase in pain in both groups, indicating that the effect was declining. The reductions in VAS after 2 yr of 3.1 points in the cervical group and 3.4 points in the lumbar group are considered to be clinically relevant. 22 The decrease in pain was re¯ected in health status. Health status of the patients measured on the EO-5D increased after SCS (Fig. 2) . This increase was the same in both groups and was mainly due to decrease in pain, discomfort, anxiety and depression.
Complications of the procedure (i.e. spinal taps, postspinal headache, no access to the epidural space and infection) were seen in six of the 36 patients. Spinal taps occurred only in the ®rst 10 patients; thereafter we changed the technique for identifying the epidural space from loss of resistance to full¯uoroscopic control. Adverse effects (i.e. technical failures) were seen in both the cervical and the lumbar group. Dislocation of the lead occurred somewhat more frequently in the cervical group, but this difference was not signi®cant.
In conclusion, SCS was effective in patients with chronic CRPS I in our study, even after 2 yr of treatment. There were no signi®cant differences in pain and quality of life between cervical and lumbar implantation of the lead. Cervical implantation was not associated with a higher complication rate.
